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MFAP4 (microfibrillar-associated protein 4) is an extracellu-
lar glycoprotein found in elastic fibers without a clearly defined
role in elastic fiber assembly. In the present study, we character-
ized molecular interactions between MFAP4 and elastic fiber
components. We established that MFAP4 primarily assembles
into trimeric and hexameric structures of homodimers. Binding
analysis revealed that MFAP4 specifically binds tropoelastin
and fibrillin-1 and -2, as well as the elastin cross-linking amino
acid desmosine, and that it co-localizes with fibrillin-1-positive
fibers in vivo. Site-directed mutagenesis disclosed residues
Phe241 and Ser203 inMFAP4 as being crucial for type I collagen,
elastin, and tropoelastin binding. Furthermore, we found that
MFAP4 actively promotes tropoelastin self-assembly. In con-
clusion, our data identifyMFAP4 as a new ligand ofmicrofibrils
and tropoelastin involved in proper elastic fiber organization.
Elastic fibers are key extracellular matrix structural elements
of connective tissues that undergo repeated stretch, such as
large arteries and the lung (1). The fibers consist of two major
components: an amorphous elastin core surrounded by a
sheath of fibrillin-richmicrofibrils (2). Elastin is a highly hydro-
phobic polymer of the soluble precursor tropoelastin (3). Tro-
poelastin is known to undergo a self-assembly process known as
coacervation (4), often believed to be a first step in the process
of elastic fibermaturation. Because of the high content of lysine
residues within the tropoelastin sequence, its assembly into a
polymeric form is stabilized by formation of desmosine cross-
links, catalyzed by the lysyl oxidase (LOX)3 enzyme family (5).
Microfibrils, the other major component of elastic fibers,
provide the structural scaffold for the deposition of elastin glob-
ules. They consist primarily of fibrillin-1 and fibrillin-2, large
glycoproteins with a high degree of homology (6). Apart from
fibrillins, numerous accessory proteins have been shown to
associate with microfibrils or elastin and promote formation of
mature fibers, including fibulins andmicrofibril-associated gly-
coproteins (MAGPs) (7–10). The importance of proper elasto-
genesis has been underscored by gene deficiency studies: mice
lacking elastin, LOX, or fibrillin-1 die shortly after birth
because of vascular abnormalities (11–13).
MFAP4 (microfibrillar-associated protein 4) is an extracellu-
lar matrix protein belonging to the fibrinogen-related domain
(FReD) family. The family includes several proteins engaged in
tissue homeostasis and innate immunity, such as FIBCD1
(fibrinogenC domain-containing 1), ficolins, and angiopoietins
(14–16). The crystal structure of the FReD of several family
members has been solved (17–19). The ligand-binding site, des-
ignated S1, is described in all the proteins and is located in close
proximity to the calcium-binding site. MFAP4 has been
reported to form homodimeric structures that further oli-
gomerize, but its definite oligomerization pattern has not been
established (20).
MFAP4 is considered to be the humanhomolog ofMAGP-36
(36-kDa microfibril-associated glycoprotein). MAGP-36 has
been found to bind elastin and collagen in a calcium-dependent
manner and to co-localize with elastin microfibrils (21, 22).
Human MFAP4 has been localized to elastic fibers in a variety
of elastic tissues, including aorta (23), skin (24), and lung (23,
25). Immunogold electronmicroscopy studies have shown that
MFAP4 localizes to elastin-associated microfibrils but not
microfibrils away from the elastin bundle (24). Together, these
observations suggest that MFAP4 may contribute to the elastic
fiber assembly and/or maintenance. Indeed, MFAP4 has been
found to interact with fibrillin-1 and promote elastic fiber for-
mation in in vitro dermal skin fibroblast cultures (26).
In this study, we aimed to verify and further characterize the
oligomerization pattern of MFAP4 and its molecular interac-
tions with well established elastic fiber components such as
tropoelastin, fibrillin-1 and -2, and LOX. We also used site-
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directedmutagenesis to determine amino acid positions critical
for the ligand-binding properties of MFAP4 based on the
sequence alignments of the predicted S1 binding site ofMFAP4
and structural homologs. Finally, we explored the role of
MFAP4 in the process of tropoelastin coacervation.
Experimental Procedures
Sequence Analysis, Alignment, and Molecular Modeling—
DNA and protein sequence analyses were performed using the
DNASTAR Lasergene v6 package. The sequence alignment of
the FReD in MFAP4, L-ficolin, FIBCD1, and tachylectin 5A
(TL5A) was conducted using the ClustalW method within the
package.
Molecular modeling of MFAP4 was performed using the
fully automated protein structure homology-modeling server
SWISS-MODEL 8.05 (27–31). The structure of L-ficolin (Pro-
tein Data Bank code 2J3O) was used as a template to model
FReD of MFAP4. An initial model was made based on the
sequence alignment of L-ficolin andMFAP4, which was further
adjusted tomatch the structural properties. A homologymodel
of FReD was built by the server, and the figures were prepared
using the MacPyMol software (DeLano Scientific).
Production of rMFAP4 Constructs—First-strand synthesis
was performed using human lung total RNA (Clontech) as
described previously (25). The coding sequence for human full-
length recombinant MFAP4 (rMFAP4) without a His6 and V5
tag was inserted into the pcDNA5/FRT/V5-His TOPOTA
(Invitrogen) expression vector as described previously (32).
In addition, several genetically modified versions of rMFAP4
containing selected point mutations within the FReD sequence
were created using the QuikChange Lightning site-directed
mutagenesis kit (Agilent Technologies, Santa Clara, CA) and
the plasmid containing the rMFAP4 as a template (Table 1).
Expression vectors containing the desired mutations were
transformed into competent cells using theQuikChange Light-
ning site-directed mutagenesis kit (Agilent Technologies)
according to the manufacturer’s instructions. The purification
of the rMFAP4-coding plasmids was performed using Gene-
JETTM plasmid miniprep kit (Thermo Fisher Scientific, Wal-
tham, MA). All the constructs were sequenced using primers
T7 and bovine growth hormone terminator reverse primer
(both provided by Eurofins MWGOperon) and the online web
service supplied by Eurofins MWG Operon. The constructs
were further analyzed for presence of desired mutations and
absence of additional mutations using SeqManTM II DNAS-
TAR Lasergene v6.
Expression and Purification of rMFAP4 WT and Mutant
Forms—The expression and purification of MFAP4 variants
was performed as described previously (25, 32).
Concentration of WT rMFAP4—Purified WT rMFAP4 was
concentrated using a Vivaspin 6 ultrafiltration spin column,
10-kDa cut-off (GE Healthcare), and the buffer was changed to
50 mM Tris, 150 mM NaCl, pH 7.5. The purity of the concen-
trated protein was tested by SDS-PAGE followed by Coomassie
staining using SimplyBlueTM SafeStain (Invitrogen). The con-
centration of WT rMFAP4 was0.7 mg/ml.
Gel Permeation Chromatography—Gel permeation chroma-
tography of WT rMFAP4 and MFAP4 mutant forms was con-
ducted on a Superdex 200 10/30 column (Amersham Biosci-
ences, GE Healthcare) in 50 mM Tris, pH 7.5, containing 150
mM NaCl. The elution profile was fitted with two Gaussian
curves. The Stokes radius ofWTrMFAP4was determined from
its elution position relative to the elution position of proteins of
known Stokes radius (thyroglobulin, ferritin, aldolase, conalbu-
min, and ovalbumin) (33).
Analytical Ultracentrifugation—Sedimentation velocity ex-
periments were carried out at 40,000 rpm and 20 °C using
aluminum centerpieces in a Beckman XL-I analytical ultracentri-
fuge (BeckmanCoulter). Scanswere collected at 3-min intervals at
230 nm (0.18mg/ml) and 1.5-min intervals at 280 nm (0.7mg/ml)
in separate experiments. The datawere analyzed by using the pro-
gramSedfitwith68and45scans, respectively (34).Theproportion
of eachcomponentof themixturewasvery similar at eachconcen-
tration, suggesting that oligomers do not interconvert appreciably
over the concentration range examined. The partial specific vol-
ume of WT rMFAP4 was calculated as 0.702 ml/g based on its
amino acid and carbohydrate composition (35).
Determination of MFAP4 Molecular Mass—The molecular
mass of theWT rMFAP4 oligomers were calculated from their
sedimentation coefficients (s20,w) and the Stokes radius derived
from the gel filtration experiment (36) and separately in the
sedimentation experiment from the spreading of the protein
boundary over time.
TABLE 1
Primer sequences used for site-directed mutagenesis of human recombinant MFAP4
Complementary sets of oligonucleotide primers of 30 bp each containing the mutagenic substitutions of interest (S203A, S203Y, F241A, F241W, D191A, D193A, and
D191A/D193A) were constructed using the QuikChange Primer Design program (Agilent Technologies).
Base change Base position Amino acid change Primer sequences
T/G 632 S203A Forward: 5-CTGCGCAGCTCTCGCCTCAGGAGCCTT-3
Reverse: 5-AAGGCTCCTGAGGCGAGAGCTGCGCAG-3
C/A 633 S203Y Forward: 5-CTGCGCAGCTCTCTACTCAGGAGCCTTCT-3
Reverse: 5-AGAAGGCTCCTGAGTAGAGAGCTGCGCAG-3
TT/GC 746–747 F241A Forward: 5-GGCCCAGTGGAAGGGCGCCTACTACTCCCTCAAA-3
Reverse: 5-TTTGAGGGAGTAGTAGGCGCCCTTCCACTGGGCC-3
TC/GG 746–747 F241W Forward: 5-GCCCAGTGGAAGGGCTGGTACTACTCCCTCAAAC-3
Reverse: 5-GTTTGAGGGAGTAGTACCAGCCCTTCCACTGGGC-3
A/C 597 D191A Forward: 5-TACCTTCGACCGGGCCCAGGACCTCTTTG-3
Reverse: 5-CAAAGAGGTCCTGGGCCCGGTCGAAGGTA-3
A/C 603 D193A Forward: 5-GACCGGGACCAGGCCCTCTTTGTGCAG-3
Reverse: 5-CTGCACAAAGAGGGCCTGGTCCCGGTC-3
A/C, A/C 597, 603 D191A/D193A Forward: 5-CCTTCGACCGGGCCCAGGCCCTCTTTGTGCA-3
Reverse: 5-TGCACAAAGAGGGCCTGGGCCCGGTCGAAGG-3
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Pulldown Assay—5 mg of type I collagen from bovine Achil-
les tendon (Sigma-Aldrich), bovine lung or aortic elastin (Elas-
tin Products Company, Owensville, MO), and chitin from
shrimp cells (Sigma-Aldrich) were washed in 1 ml of TBS,
0.05%Tween, 5mMCaCl2 (TBST-Ca) containing 1mg/ml BSA
(Sigma-Aldrich) and hydrated in TBST-Ca overnight at 4 °C.
Macromolecules were pelleted and incubated with 31 ng/ml
WT rMFAP4 or purified mutant MFAP4 variants (diluted in
TBST-Ca or TBST containing 10 mM EDTA, 1 ml of total vol-
ume) overnight at 4 °C. The supernatants were removed, and
the pellets were washed with TBST-Ca containing 1 mg/ml
BSA. Bound protein was eluted from the insoluble fraction by
boiling the samples in SDS-PAGE buffer (40% (v/v) glycerol, 8%
(w/v) SDS, 25% (v/v) 4 lower Tris, pH 8.8, 0.002% bromophe-
nol blue) and subsequently analyzed by SDS-PAGE and West-
ern blotting.
SDS-PAGE and Western Blotting—The samples were mixed
with SDS-PAGE buffer with 0.6 M DTT in the reduced samples
or 0.02 M iodoacetamide in the nonreduced samples. The sam-
ples were boiled for 1 min and finally alkylated by the addition
of 1.4 M iodoacetamide to a final concentration of 90 mM. Pro-
teins were separated by SDS-PAGE and transferred to a PVDF
membrane (Amersham Biosciences). The membrane was
blocked with 5% nonfat dry milk (Bio-Rad) in TBST for 2 h at
room temperature and incubated with 0.5g/ml HG-HYB 7–5
anti-MFAP4 antibody at 4 °C overnight. The membrane was
washed in TBST and incubated with rabbit anti-mouse Ig-HRP
(Dako, Glostrup, Denmark), diluted 1:20,000 for 1 h at room
temperature. Proteins were detected using ECL reagents
(Amersham Biosciences).
Production of Recombinant Fibrillin Fragments—Recombi-
nant fragments of human fibrillin-1 were overexpressed in
HT1080 or HEK293/EBNA cells and purified using anion
exchange chromatography as previously described (37, 38). The
fibrillin-1 N-terminal unique region including the first epider-
mal growth factor (EGF)-like domain fused together with
cbEGF19–22 and a tandemC-terminal Strep tagwas expressed
and purified as previously described (39) (Fig. 1A and Table 2).
Recombinant fragments spanning human full-length fibril-
lin-2 were overexpressed with a tandemC-terminal StrepII-tag
FIGURE 1. Structure of recombinant fibrillin fragments.A, domain structure of full-length fibrillin-1 and recombinant fibrillin-1 fragments used in this study.
B, domain structure of full-length fibrillin-2 and recombinant fibrillin-2 fragments used in this study. Details of the domains are given in the legend. C, purity of
recombinant fibrillin-2 fragments was analyzed by SDS-PAGE and silver staining. D, purity of recombinant fibrillin-1 fragments rF87 and fibrillin-1 N-terminal
unique region (FUN) was analyzed by SDS-PAGE and Coomassie blue staining.
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followed by purification using affinity chromatography as pre-
viously described (39) (Fig. 1B and Table 2). After transfection
of HEK293 cells, stably transfected clones were selected in the
presence of puromycin (1 g/ml). Proteins were purified
directly from serum-free cell culture medium. After filtration
and centrifugation (25 min, 10,000  g) culture supernatants
were applied to a Streptactin column (1 ml; IBA, Goettingen,
Germany) and eluted with 2.5 mM desthiobiotin, 10 mM Tris-
HCl, pH 8.0.
Solid Phase Binding Assays—Plates were coated with tro-
poelastin (Sigma-Aldrich; 100 ng/ml), fibrillin-2 fragments
(100 ng/ml), MFAP4 (500 ng/ml), full-length LOX (500 ng/ml;
Origene, Rockville,MD), ovalbumin-desmosine conjugate (500
ng/ml; Elastin Products Company), or ovalbumin (500 ng/ml;
Sigma-Aldrich) diluted in coating buffer (CO32/HCO3, pH
9.6) and incubated at 4 °C overnight. The next day the plates
were washed three times with TBST-Ca and blocked with
TBST-Ca containing 10 mg/ml BSA for at least 1 h at room
temperature. Plates were then incubated with MFAP4 variants
or recombinant LOX (OriGene) at the indicated concentra-
tions diluted in TBST-Ca or TBST containing 10mMEDTA for
2 h at room temperature. The plates were washed in TBST-Ca
and incubated with 0.5 g/ml biotinylated HG-HYB 7–5 anti-
MFAP4 antibody or 1 g/ml biotinylated anti-LOX (OriGene)
for 1 h at room temperature, washed again, and subsequently
incubated with 0.625 g/ml streptavidin-HRP conjugate
(Zymed; Thermo Fisher Scientific) for 30 min at room tem-
perature. After the final wash, the plates were developed
using 2 mg O-phenylenediamine dihydrochloride (Kem-En-
Tec, Taastrup, Denmark) dissolved in 5ml of citrate phosphate
buffer, pH 5.0, with 35% (w/v) H2O2. The reaction was stopped
with 1 M H2SO4, and the absorbance was read at 492 nm versus
620 nm. The signal from background binding to ovalbumin (for
ovalbumin-desmosine) or BSA (all other proteins) was sub-
tracted from the results. In some experiments, WT rMFAP4
was preincubated with increasing concentrations of tropoelas-
tin or deoxypyridinoline cross-links (Santa Cruz Biotechnol-
ogy; WT rMFAP4 concentrations: 125 or 500 ng/ml, respec-
tively) for 2 h at room temperature before adding to the blocked
plate.
In a separate set of experiments, plates were coated with 0.1
MMFAP4 in PBS containing 5mMCaCl2.Wells were blocked
with 5%nonfat drymilk inTBS for 1 h at room temperature and
incubated with recombinant fibrillin-2 fragments (serial dilu-
tions starting from 500 nM) in 2% milk in TBS for 3 h at room
temperature. Bound C-terminally double Strep-tagged fibril-
lin-2 variants were detected using a monoclonal anti-Strep tag
antibody (StrepMAB-Classic; IBA) diluted in 2% milk in TBS,
after a final incubation with enzyme-conjugated secondary
antibodies. Color reaction was achieved using 3,3,5,5-tetram-
ethylbenzidine (Sigma-Aldrich). The reactionwas stoppedwith
0.1 N HCl, and the absorbance was read at 450 nm.
Surface Plasmon Resonance (SPR)—SPR experiments were
performed using a BIAcore 2000 (BIAcore AB, Uppsala, Swe-
den). MFAP4 was covalently coupled to CM5 sensor chips at
2500 Rus and fibrillin-1 or -2 fragments were flown over at 100
nM inHBS-P buffer (BIAcoreAB) containing either 5mMCaCl2
or 3 and 10 mM EDTA.
In a separate set of experiments, ovalbumin and ovalbumin-
desmosine conjugate were flown over immobilized MFAP4 at
50 nM. Alternatively, tropoelastin was coupled to sensor chips
andWT rMFAP4 andMFAP4mutant variants were flown over
at 1000 nM.
Immunofluorescence Microscopy—Skin biopsies from male
C57BL/6 WT and GT-8 mice (40) sacrificed at postnatal day 1
(P1), P7, and P14 were snap frozen in liquid nitrogen and then
embedded in Tissue-Tek O.C.T. compound (Sakura Finetek
Europe, Alphen aan Den Rijn, the Netherlands). Seven-m-
thick cryosections were cut using a Leica CM1850 cryostat.
Sections were air dried for 15 min at room temperature and
were then fixed for 10 min in cold acetone/methanol, blocked
with 1% BSA in PBS for 45 min, and incubated with primary
antibodies rabbit anti-fibrillin-1 pAb 9543 (41) andmonoclonal
mouse anti-MFAP4 (32) diluted 1:1000 in PBS/1% BSA over-
night at 4 °C in a humidified chamber. After washing in PBS,
sections were incubatedwith FITC-conjugated goat anti-rabbit
antibody diluted 1:1000 in PBS, 1% BSA and Cy3-conjugated
goat anti-mouse antibody (both from Life Technologies,
Thermo Fisher Scientific) diluted 1:100 in PBS, 1% BSA for 60
min at room temperature. The sections were washed thor-
oughly, coverslipped using the Dako Fluorescence Mounting
Medium (Dako), and visualized with a Leica SP5 confocal laser
microscope. Micrographs were processed using the ImageJ
software (42).
Coacervation Assay—Soluble tropoelastin and WT rMFAP4
or BSA were mixed in TBST-Ca to final concentrations of 1
mg/ml and 40g/ml, respectively, and kept on ice. The reaction
mixtures (50 l) were transferred to a 96-well plate, and the
absorbance at 405 nm was measured at different temperatures
ranging from 19 to 45 °C using Victor3 plate reader (PerkinEl-
mer Life Sciences).
Statistics—Quantitative data were analyzed using Prism 5
software (GraphPad, La Jolla, CA) and are presented as
means  S.E. unless stated otherwise. The results were ana-
lyzed using unpaired Student’s t test or two-way analysis of
variance, with p values of0.05 considered significant.
Results
MFAP4 Forms Trimers and Hexamers of Homodimers—To
investigate the structural organization and oligomerization of
human MFAP4, we produced full-length rMFAP4. On SDS-
PAGE,WT rMFAP4migrated equivalent to amonomeric form
(36 kDa) in the reduced state and to a homodimer (66 kDa)
TABLE 2
Recombinant fragments spanning full-length fibrillin-1 and -2
Fibrillin fragment
Origin
protein Spanned region
rF11 Fibrillin-1 Ser19--Val1527
rF6 Asp1487--His2871
rF20 Pro402--Val1527
rF87 Ser19--Ile329
FUN Ser19--His118 fused to Asp1363--Val1527
rF86 Fibrillin-2 Gln29--Asp535
Glycinr-cbEGF10 Glu412--Asp997
cbEGF10-cbEGF24 Val956--Asp1734
cbEGF23-cbEGF33 Ile1651--Asp2253
cbEGF32-cbEGF38 Val2172--Asp2532
cbEGF37-end Ile2450--Tyr2912
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in the nonreduced state (Fig. 2A) as previously described (25).
Further gel filtration chromatography analysis revealed that
WT rMFAP4 eluted as two overlapping peaks corresponding to
Stokes radii of 5.4 and 7.0 nm (Fig. 2B).
Analytical ultracentrifugation was used to determine the
sedimentation coefficient of WT rMFAP4. Four species were
detected by sedimentation velocity experiments of WT
rMFAP4: 10.1 S, 51%; 13.1 S, 7%; 16.2 S, 35%; and 20.2 S, 3% (Fig.
2D). The same proportion of each size of oligomers was
observed with dilution of the protein, suggesting that the olig-
omers do not interconvert. Combining the values from the gel
filtration with the sedimentation coefficients, s20,w, gives
molecular masses of 208 and 432 kDa for the major species,
thus suggesting trimeric and hexameric structures of homo-
dimers (6- and 12-mer, respectively). Similar values (197 and 399
kDa) were calculated directly by Sedfit, which estimates the diffu-
sion coefficient, and hence the Stokes radius, from the spreading
of the protein boundary over time. Minor species of 289 and 553
kDa probably comprise tetrameric and octameric structures of
homodimers (8- and 16-mer, respectively).
FIGURE 2.Oligomerization of humanMFAP4. A, purified and concentrated recombinantWTMFAP4 (WT rMFAP4). Lanes 1 and 2 show the purified protein in
reduced and nonreduced state, respectively. Lanes 3 and 4 show concentrated WT rMFAP4 in reduced and nonreduced state, respectively. B, gel filtration
elution profile ofWT rMFAP4. Protein eluted as twooverlapping peaks, and the elution profilewas fittedwith twoGaussian curves (dotted lines) corresponding
to Stokes radii of 5.4 and 7 nm. Elution positions of bovine thyroid thyroglobulin (arrow T; 669 kDa), horse spleen apoferritin (arrow F; 440 kDa), rabbit muscle
aldolase (arrow A; 158 kDa), conalbumin (arrow C; 75 kDa), and ovalbumin (arrow O; 43 kDa) are indicated. C, sedimentation of WT rMFAP4 (every third scan is
shown). D, distribution of sedimenting species c(s) of WT rMFAP4. The data were fitted using continuous c(s) distribution using SEDFIT package. Four species
were detected: 10.1 S (51%), 13.1 S (7%), 16.2 S (35%), and 20.2 S (3%).
MFAP4 Interactions with Tropoelastin and Fibrillins
JANUARY 15, 2016•VOLUME 291•NUMBER 3 JOURNAL OF BIOLOGICAL CHEMISTRY 1107
 at D
EF Consortium
 - U
niv Library of Southern D
enm
ark on June 9, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Binding ofHumanMFAP4 to Elastin andCollagen—Weused
a site-directed mutagenesis strategy based on sequence align-
ments to compare the S1 binding site of MFAP4 and FIBCD1.
Despite different ligand specificities, binding in all well charac-
terized FReD familymembers ismediated at least in part via the
S1 pocket. Comparison with FIBCD1, L-ficolin, and TL5A
shows that of the six residues that are likely to form the S1
pocket inMFAP4, three residues are identical in all other family
members (Cys212, His213 andAla230), one is conserved in two of
the three members (Tyr229), and the other two residues are
different (Fig. 3A). Notably, Ser203 is a hydrophobic residue in
FIBCD1, L-ficolin, andTL5A, whereas Phe241 is a tryptophan or
a tyrosine. For mutagenesis, the serine in position 203 and the
phenylalanine in position 241 weremutated to the correspond-
ing amino acids in FIBCD1 or to the simple amino acid alanine.
The objective of these experiments was to change the S1 bind-
ing pocket in MFAP4 and thereby disrupt binding toward
MFAP4-specific ligands but to retain the integrity of the fibrin-
ogen-like fold via conservative substitutions to the correspond-
ing residues in FIBCD1. All four variant forms of rMFAP4
(S203A, S203Y, F241A, and F241W) were secreted normally
and eluted at positions similar to WT rMFAP4 when analyzed
by gel filtration chromatography (Fig. 3B), indicating that the
mutations did not compromise biosynthesis or folding of the
proteins. Fig. 3C shows the modeling of the predicted S1 bind-
ing pocket ofWTMFAP4.We further attempted to investigate
the involvement of calcium binding in MFAP4 interactions by
mutating two conserved aspartate residues in positions 191 and
193 to alanine (D191A, D193A, and D191A/D193A). However,
we were not able to obtain functional proteins for any of the
three mutations (data not shown), indicating that the intro-
duced changes compromised correct biosynthesis and/or fold-
ing of the proteins.
Human WT rMFAP4 bound elastin and type I collagen in a
calcium-dependent manner (Fig. 4A) as previously demon-
strated for a bovine homolog (21). MFAP4 variants exhibited
altered binding pattern to both ligands. Mutation S203A did
not influence MFAP4 binding capacity. Mutation S203Y mod-
erately lowered binding to elastin but potently attenuated bind-
ing to type I collagen. Themutations in position Phe241 had the
strongest influence on MFAP4 binding properties, with both
F241A and F241W variants showing strong attenuation or
complete inhibition of interactions with elastin and type I col-
lagen, respectively (Fig. 4, B and C).
MFAP4 Interacts with Tropoelastin—Because MFAP4 is
known to co-localize with elastic fibers, we investigated its
FIGURE 3. Structure of the S1 binding site of MFAP4. A, sequence alignment of the S1 site in MFAP4, FIBCD1, L-ficolin, and TL5A. The numbers on top and
bottom refer toMFAP4 and TL5A sequences, respectively. Conserved residues are highlighted in gray. Residues in the S1 site aremarked in red. Themutations
performed in this study are indicated. The accession numbers were as follows: MFAP4, AAH62415.1; L-ficolin, NP_001994.2; FIBCD1, NP_116232.3; and TL5A,
1JC9_A.B, gel filtration elutionprofile ofMFAP4mutant variants. Elutionpositions ofWT rMFAP4are indicatedwithdashed lines.C,modelingof S1binding site
inWTMFAP4,with the indicatedaminoacidsmutated in this study. The structureof L-ficolin (ProteinDataBank code2J3O)wasusedas a template formodeling
by SWISS-MODEL 8.05, and the figures were prepared using MacPyMOL software.
FIGURE4.BindingofMFAP4 to insolubleelastinand type I collagen.A,WT
MFAP4 binds to elastin and type I collagen, but not chitin (negative control),
in a calcium-dependentmanner.MFAP4 is pulleddownby insoluble collagen
or type I collagen but remains in solution in the presence of EDTA. B, point
mutations within S1 site influence binding of MFAP4 to elastin and type I
collagen. Although mutation S203A does not impact MFAP4 binding capac-
ity, mutation S303Y lowers andmutations F241A and F241W strongly reduce
elastin andcollagenbindingpropertiesofMFAP4.C, densitometric analysis of
(B) normalized to WT rMFAP4 (indicated with a dashed line). The data are
representative (A and B) or means  S.E. (C) of at least two independent
experiments.
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molecular interactions with tropoelastin. Specific binding
between WT rMFAP4 and immobilized tropoelastin was
detected in a solid phase binding assay (Fig. 5A). The interac-
tion was crucially dependent on calcium ions, because addition
of EDTA fully inhibited observed effects (Fig. 5A). Moreover,
the interaction was attenuated by WT rMFAP4 preincubation
with soluble tropoelastin, confirming the specificity of our
results (Fig. 5B). Mutant MFAP4 forms S203Y, F241W, and
F241A exhibited significantly diminished binding to tropoelas-
tin, whereas mutation S203A had no impact on the binding
(Fig. 5C). Furthermore, SPRmeasurements showed a clearWT
rMFAP4 binding to immobilized tropoelastin, whichwas unde-
tectable in case of all four MFAP4 mutant variants (Fig. 5D).
MFAP4 Interacts with Fibrillin-1 and -2 in Vitro and Co-lo-
calizes with Fibrillin-1 Fibers in Vivo—To test direct interac-
tion of MFAP4 with fibrillins, a direct SPR interaction screen
was performed using fibrillin truncation variants spanning full-
length fibrillin-1 and -2 (Fig. 1, A and B). These binding exper-
iments revealed distinct binding epitopes for MFAP4 within
fibrillin-1 and fibrillin-2. Fibrillin-1 variants rF11 and rF87
(Figs. 1A and 6A) specifically interacted with immobilized WT
rMFAP4, suggesting that the MFAP4 binding site lies within
the N-terminal part of fibrillin-1 containing the second and
third EGF-like domains, the first hybrid motif, and the first two
cbEGF-like domains (Fig. 6C). A fragment covering the N-ter-
minal unique region and the first EGF-like domain (fibrillin-1
N-terminal unique region) showed no binding (Fig. 6A), indi-
cating that these domains are not involved inMFAP4-fibrillin-1
interaction.
Among fibrillin-2 variants, fragments rF86 and EGF23–33
bound to immobilized WT rMFAP4 (Fig. 6B). We confirmed
our results using solid phase binding assays, where fragments
rF86 and cbEGF23–33 bound WT rMFAP4 in a dose-depen-
dent manner (data not shown). Thus, MFAP4 is able to bind
fibrillin-2 at two distinct sites (Fig. 6C). The binding of both
fibrillin-1 and fibrillin-2 fragments to WT rMFAP4 was not
calcium-dependent, because the interaction was unchanged in
the presence of EDTA (data not shown).
To confirm our in vitro observations, we performed co-local-
ization studies in murine skin sections of WT mice and GT-8
mice, with the latter expressing a dominant negative mutant
form of fibrillin-1 that causes progressive elastic fiber fragmen-
tation (40). At day P1, when fibrillin-1 fibers in GT-8 mice look
normal, MFAP4 and fibrillin-1 show only partially overlapping
staining patterns (Fig. 6D). However, we detected strong co-lo-
calization of MFAP4 and fibrillin-1 at P7 and P14 time points,
both in WT and GT8 tissues. In GT-8 skin at P14, MFAP4
exhibited a punctate staining pattern of the fragmented fibers,
similar to fibrillin-1 (Fig. 6D).
MFAP4 Binds LOX but Does Not Tether LOX to Tropo-
elastin—In solid phase binding experiments, WT rMFAP4 was
able to bind immobilized LOX (Fig. 7A). We then checked
whether MFAP4 could act as a bridging protein and facilitate
the binding of LOX to immobilized tropoelastin. However, we
detected only a weak binding between LOX and tropoelastin,
and the presence ofWT rMFAP4 had no effect on this interac-
tion (Fig. 7B). Thus,MFAP4 does not assist in tethering LOX to
tropoelastin.
Binding of MFAP4 to Desmosine—We detected calcium-de-
pendent binding betweenWT rMFAP4 and ovalbumin-conju-
gated desmosine using solid phase binding setup (Fig. 8A). We
confirmed our observations by SPR measurements, where we
detected binding between immobilized WT rMFAP4 and
ovalbumin-conjugated desmosine but not the ovalbumin con-
trol (Fig. 8B). Preincubation of MFAP4 with collagen-specific
deoxypyridinoline cross-links did not influence MFAP4 bind-
ing to desmosine (data not shown).
We also investigated whether binding to desmosine is dis-
rupted by point mutations in the S1 binding site of MFAP4.
Indeed, both Phe241 mutants and the S203Y mutant exhibited
abolished or attenuated binding, underlying the importance of
these two positions in mediating proper interactions with the
ligand (Fig. 8C).
MFAP4 Promotes Coacervation of Tropoelastin—Finally, we
investigated whether MFAP4 can influence the ability of tro-
poelastin to coacervate. Recombinant tropoelastin began to
coacervate spontaneously at 37 °C. In the presence of WT
rMFAP4, tropoelastin started to coacervate at lower tempera-
tures, showing that MFAP4 promotes tropoelastin self-assem-
bly (Fig. 9). Tropoelastin coacervation was not induced in the
presence of negative control protein BSA (Fig. 9). No change in
turbidity was observed for the buffer or WT rMFAP4 alone.
Discussion
Although elastic fiber assembly is a criticalmolecular process
responsible for proper function of elastic tissues, it still remains
poorly understood. In the present study,we investigatedmolec-
ular composition of MFAP4 and its interactions with elastic
fiber components.We identifiedMFAP4 as a tropoelastin- and
fibrillin-binding protein and pinpointed the specific residues in
FIGURE 5. Molecular interactions between MFAP4 and tropoelastin. A,
MFAP4 binds immobilized tropoelastin in a calcium-dependent manner in
solid phase binding assays. B, MFAP4 interactionwith immobilized tropoelas-
tin is attenuated by preincubatingMFAP4with soluble tropoelastin. C, muta-
tions of the S1 binding site modify MFAP4-tropoelastin binding capacity. D,
BIAcore analysis of binding between immobilized tropoelastin and soluble
MFAP4 variants. One representative experiment is shown. The data are
means S.E. of three independent experiments. **, p 0.01; ***, p 0.001,
calculated by Student’s t test.
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theMFAP4 structure responsible for its binding capacities.We
also showed that MFAP4 facilitates tropoelastin coacervation.
Our results revealed new details of elastic fiber assembly pro-
cess, thus providing a better understanding of elastic fiber biol-
ogy (Fig. 10).
The multimerization and oligomeric state of FReD-contain-
ing proteins is considered to be important to establish a confor-
mation that matches the spatial organization of their ligands,
such as branched oligosaccharides, and thereby to increase the
binding strength (15, 43). Using chemical cross-linking, it has
been suggested that MFAP4 homodimers assemble into higher
oligomeric forms of 280 kDa, corresponding to an 8-meric
structure (25). This has been supported by gel permeation chro-
matography of rMFAP4, which eluted as a single peak corre-
sponding to a size between 158 and 335 kDa (32). However, our
results from gel permeation chromatography and ultracentrif-
ugation suggest that MFAP4 primarily forms 6- and 12-meric
structures with molecular masses of 208 and 432 kDa, respec-
tively, together withminor species of 8- and 16-mers. Observed
differences might be caused by the choice of column; we used
the Superdex 200 with higher resolution than the Superose 6
used in the previous studies. In addition, we have previously
observed that in physiologically relevant concentrations in
FIGURE 6. Molecular interactions between MFAP4 and fibrillins. A, BIAcore analysis of binding between immobilized MFAP4 and soluble fibrillin-1 frag-
ments flownover at 100nM in thepresenceof 5mMCaCl2.One representative experiment is shown.B, BIAcore analysis of bindingbetween immobilizedMFAP4
and soluble fibrillin-2 fragments flown over at 100 nM in the presence of 5 mM CaCl2. One representative experiment is shown. C, structure of full-length
fibrillin-1 and fibrillin-2with identifiedMFAP4binding sites (red rectangles).D, confocal immunofluorescencemicroscopy shows co-localization ofMFAP4 (red)
and fibrillin-1 (green) in the skin ofWT andGT-8mice (GT-8/GT-8) at postnatal days P1, P7, and P14. Representative pictures are shown. Originalmagnification,
126. Scale bar, 20 m.
FIGURE 7. Molecular interactions between MFAP4 and LOX. A, MFAP4
binds to immobilized LOX. B, the interaction between LOX and immobilized
tropoelastin is not influenced by the presence of MFAP4 in the solution. The
data are means S.E. of three independent experiments.
FIGURE 8. Molecular interactions between MFAP4 and desmosine. A,
MFAP4 binds immobilized ovalbumin-desmosine conjugate in a calcium-de-
pendent manner in solid phase binding assays. The background binding to
ovalbumin was subtracted from the results. B, BIAcore analysis of binding
between immobilized MFAP4 and soluble ovalbumin-desmosine conjugate
and ovalbumin control. One representative experiment is shown. C, muta-
tions of the S1 binding site modify MFAP4-desmosine binding capacity. The
data are means S.E. of three independent experiments. *, p 0.05; **, p
0.01; ***, p 0.001, calculated by Student’s t test.
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human serum,MFAP4 elutes as a single peak that possibly rep-
resents the 6-meric form (32). This suggests that the 6-mer is
the functionally important form of MFAP4 and, importantly,
remains the main oligomeric form of purified WT rMFAP4.
The higher 12-meric oligomer might appear only in concen-
trated MFAP4 solutions.
We detected specific binding between MFAP4 and tro-
poelastin, as well as between MFAP4 and both fibrillins. This
partially contradicts previous observations of Kasamatsu et al.
(26), who suggested interaction betweenMFAP4 and fibrillin-1
but not tropoelastin. These discrepanciesmight result from the
choice of method and technical conditions, because we showed
that although fibrillin binding to MFAP4 is calcium-indepen-
dent, MFAP4 interactions with tropoelastin require calcium
ions.We confirmedour SPRbinding data in solid phase binding
assays leading to similar results. Moreover, the coacervation-
promoting properties of MFAP4 further confirm our findings,
identifying MFAP4 as a novel tropoelastin ligand.
We extended the knowledge of the MFAP4-fibrillin-1 inter-
action by identifying that the MFAP4 binding site resides
within five domains on the fibrillin-1 N terminus, containing
the second and third EGF-like domains, the first hybrid motif,
and the first and second calcium-binding EGF-like domains
(Cys119–Ile329). Our interaction studies with fragments span-
ning full-length fibrillin-2 suggest that in addition to the N-ter-
minal binding site localized to the corresponding region iden-
tified in fibrillin-1, an additional MFAP4 binding site is located
on the C-terminal half within the region encompassed by the
fifth and sixth 8-cysteine domain (Met1735–Asp2171). Fibrillin-1
and fibrillin-2 have both distinct and overlapping biological
roles. Fibrillin-2 ismostly produced during embryogenesis, and
its expression is turned off shortly after birth, whereas fibril-
lin-1 production continues throughout adulthood (44).
Although both fibrillins can be found in equal amounts in fetal,
heteropolymeric microfibrils, fibrillin-2 is largely absent or
obscure inmost postnatal tissues (41). The presence of an addi-
tional MFAP4 binding site on fibrillin-2 suggests that MFAP4
might be important during embryonic development.
GT-8/GT-8 homozygous mice exhibit fragmented microfi-
brils from around day P7 and die within 2–3 weeks after birth
(40). Importantly, we observed that MFAP4 co-localizes with
fibrillin-1 in vivo in healthy skin and remains bound to fibril-
lin-1 also in degenerating elastic fibers. This might indicate a
role for MFAP4 in diseases characterized by fibrillin degrada-
tion, such as Marfan syndrome. Marfan syndrome is caused by
mutations in fibrillin-1 gene, and itsmost seriousmanifestation
is aortic aneurysm and dissection of the ascending aorta (45).
Importantly, MFAP4 protein is up-regulated in ascending aor-
tic samples frompatients suffering fromMarfan syndrome (46),
suggesting thatMFAP4might play an important role inMarfan
syndrome pathology and aneurysm formation.
Calcium independence of the MFAP4-fibrillin interaction
suggests that fibrillins may interact with MFAP4 at a binding
site distinct from the S1 site. Interestingly, the MFAP4 binding
site is located around the first hybrid motif in the N-terminal
part of fibrillin-1, the region recognized also by MAGP-1 and
fibulin-5, known for facilitating tropoelastin-fibrillin interac-
tions (7, 47). Considering the ultrastructural localization of
MFAP4 at the elastin-microfibril interface, it may be hypothe-
sized that MFAP4 acts as a bridging molecule that guides tro-
poelastin deposition onto microfibrils.
FIBCD1 is a FreD protein with the highest homology to
MFAP4. Phylogenetically, the FReDs of MFAP4 and FIBCD1
are closely related (48), and the homologous S1 ligand-binding
site can be predicted within the FReD of MFAP4. Analysis of
the crystal structure of FIBCD1 revealed that the hydrophobic
binding pocket of FIBCD1 is created by the aromatic side chains
of Tyr405 (MFAP4, Ser203), His415 (MFAP4, His213), Tyr431
(MFAP4, Tyr229), andTrp443 (MFAP4, Phe241) (17). All of these
residues were found to be important for FIBCD1 binding to
acetylated structures, with slight binding impairment for
Trp443 mutant and total inhibition for the remaining three
mutants (49).
FIGURE 9.MFAP4 promotes tropoelastin coacervation. Self-aggregation
of 1mg/ml of soluble tropoelastinwas induced in the presence or absence of
recombinant WT MFAP4 by the increase in temperature, and the turbidity of
the solution was measured. TBST-Ca, TBS/0.05% Tween containing 5 mM
CaCl2. The data are means  S.E. of two independent experiments. **, p 
0.01; ****, p 0.0001, calculated by two-way analysis of variance.
FIGURE10.AmodeldescribingtheproposedroleofMFAP4 inelastic fiber
assembly. MFAP4 binds to tropoelastin and promotes tropoelastin coacer-
vation (step 1). Tropoelastin is further cross-linked by LOX, recruited by fibu-
lin-4 (step 2). MFAP4 and other proteins such as fibulin-5 interact with fibril-
lin-1 as well as tropoelastin (step 3) and guide tropoelastin complex
deposition ontomicrofibrils, resulting in a formation of a mature elastic fiber
(step 4). Fibulin interactions have been described previously (8).
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We chose to mutate two residues in the predicted S1 site of
MFAP4 that are not conserved with regards to FIBCD1
sequence, namely Ser203 and Phe241. Variants S203A, S203Y,
and F241A oligomerized toward a 6-mer, similarly to WT
rMFAP4, whereas variant F241W assembled mainly into a
12-mer. This suggests that the substitution of Phe241 with tryp-
tophan promotes formation of a larger oligomer. We showed
that single amino acid change in either of these positions influ-
encesMFAP4 binding properties. Overall, MFAP4 interactions
were compromised the most by mutations of Phe241. Phe241 is
most likely involved in maintaining the hydrophobicity of the
binding pocket. However, replacing it with another hydropho-
bic amino acid (F241W) also resulted in binding deficiency,
implying that this substitutionmight have introduced an unac-
ceptable steric hindrance. Because variant F241W, unlike other
investigated mutants, polymerized predominantly toward a
12-mer, it is also possible that the 12-meric form of MFAP4 is
relatively inactive compared with the main, 6-meric form.
Interestingly, MFAP4 ligand binding was attenuated in S203Y
but not S203A variant. This suggests that the hydroxyl group of
Ser203 is not essential for binding, but the proper size of the
amino acid in this position might ensure the proper conforma-
tion of the binding site or maintenance of contacts between
other residues involved in the ligand recognition.
To our knowledge, MFAP4 is the first described desmosine-
bindingmolecule. The desmosine cross-link is derived from the
condensation of four lysine residues and occurs only in mature
elastin (1). The presence of soluble desmosine in body fluids is
an indicator of elastic fiber degradation and has been suggested
as a biomarker for lung damage (50, 51). Interestingly, we have
recently shown that plasma MFAP4 is associated to chronic
obstructive pulmonary disease (COPD) severity and may serve
as a stable COPD biomarker (52). The interaction between
MFAP4 and desmosine seems specific, as shown by lack of
competition by collagen-specific deoxypyridinoline cross-
links. We speculate that the interaction of MFAP4 and des-
mosine may contribute to mature elastic fiber homeostasis and
stability.
Cross-linking of tropoelastin aggregates is an important step
in the development of mature elastic fibers, catalyzed by LOX
andLOX-like proteins (LOXL1–4). Because of sequence differ-
ences in their pro-peptide regions, functional differences
between LOX family members have been suggested (53).
Indeed, at least LOXL1 has been shown to play a nonredundant
role in elastic fiber homeostasis with ligand specificities distinct
from LOX (54). Despite a detectable binding between LOX and
MFAP4, our data did not support a role for MFAP4 in recruit-
ing LOX to tropoelastin. However, we cannot exclude the pos-
sibility thatMFAP4 interacts with LOXLs and thus contributes
to cross-link formation.
Tropoelastin-binding proteins can exhibit coacervation-pro-
moting properties, as previously demonstrated for fibulin-5 or
fibrillin-1 (55, 56). We showed that MFAP4 not only binds
strongly to tropoelastin but also promotes tropoelastin coacer-
vation. Coacervation is believed to be crucial for initial concen-
tration and proper aligning of tropoelastin molecules before
cross-linking (4, 57, 58). Importantly, impaired coacervation is
a cause of abnormal elastic fiber assembly in the patients with
supravalvular aortic stenosis in whom mutant tropoelastin
secretion is not impaired (59, 60). Thus, molecular interactions
between tropoelastin and MFAP4 might positively affect the
alignment and maturation of tropoelastin. Because we con-
firmed previously suggested interactions between MFAP4 and
fibrillin-1 (26), it is also possible that MFAP4 together with
fibrillin-1 cooperatively promote coacervation.
MFAP4 has been hypothesized to share functions with
another extracellular matrix protein, fibulin-5 (21). Fibulin-5
also contains an RGD sequence, exhibits elastin-binding prop-
erties, and is essential for elastogenesis in vivo (61, 62). The
functional overlap betweenMFAP4 and fibulin-5 was also pre-
dicted in the recent genome-wide gene expression study, where
gene expression of MFAP4 and fibulin-5 in the lung tissue
strongly correlated with each other and were both highly up-
regulated in patients with COPD (63). Moreover, the overlap
between MFAP4 and fibulin-5 binding sites within fibrillin-1
further strengthens the hypothesis that at least some functions
of MFAP4 are shared with fibulin-5.
We have recently generated MFAP4-deficient mice and
shown that they exhibit attenuated airway smooth muscle
responses when subjected to an allergic asthmamodel (64).We
have further investigated the steady state phenotype ofMFAP4
deficiency and observed thatMFAP4-nullmice develop a spon-
taneous loss of lung function with moderate emphysema-like
airspace enlargement, which progresses with age (65). How-
ever, the elastin protein content and elastic fiber ultrastructure
were unchanged between genotypes, and we have not detected
any obvious defects in other elastic organs in naïve MFAP4-
deficient mice.4 This suggests that the role of MFAP4 in elastic
fiber formationmight be redundant in vivo and implies involve-
ment of compensatory mechanisms.
In summary, we have shown that MFAP4 is an important
elastic fiber component. Our study provides a novel molecular
explanation for an active role of MFAP4 in elastic fiber
formation.
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